Physidia, the French company specialized in the development, production, and commercialization of an innovative and mobile home hemodialysis system, continues its expansion in Europe by signing a new distribution agreement with Nordic Medcom. The aim of the agreement is the promotion and commercialization of the S3 system and its related therapy in Sweden, Finland, Denmark and Norway.

Since its foundation in 2010, Physidia has always kept its focus on providing innovations and expertise for improving safety and simplicity of dialysis therapies for end-stage renal disease patients at home. The S³ system has been designed specifically to answer the needs of patients for a more flexible, easy-to use and mobile home dialysis equipment. In 2017, Physidia has started its international development with the ambition to make benefit patients from all around Europe from its disruptive technology for home hemodialysis.

Nordic Medcom has been working within the renal business since 2001. The company has been a leading provider of home hemodialysis therapies in their territory since 2011 and has decided to further grow its business within the sector together with Physidia. The equipment proposed by Physidia fits perfectly into the strategy of Nordic Medcom for delivering safe, simple, and secure home hemodialysis to patients, together with an outstanding service the market is used to.

As Mats Grenner, President of Nordic Medcom, explains: “Provide best level service together with a premium device are the winning concepts of Nordic Medcom. Our vision is to be recognized as an active developer of the flexibility and mobility in the different modalities of dialysis. We want to achieve this with the motto “Big enough to cope, Small enough to care” in mind.”